Zymeworks reports FY 2023 net loss of $118.7M; zanidatamab BLA initiated; cash runway into 2027

Zymeworks Inc.

Revenue $76.0M vs $412.5M in 2022, reflecting non-recurring Jazz upfront; net loss of $118.7M vs net income $124.3M.
Cash, cash equivalents and marketable securities $456.3M as of Dec 31; with milestone payments, runway into 2H 2027.
Rolling BLA for zanidatamab in second-line biliary tract cancers started by Jazz; expected completion 1H 2024.
Jazz initiated Phase 3 confirmatory trial for zanidatamab as first-line BTC; BeiGene expects NMPA BLA filing 2H 2024.
Targeting two IND submissions in 2024 (ZW191, ZW171); ZW49 Phase 2 deprioritized pending collaboration.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Zymeworks Inc. reported financial results for the fourth quarter and year ended December 31, 2023.

Period: the fourth quarter and year ended December 31, 2023
Result: reported results

Exact text from the filing

Zymeworks Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter and fiscal year ended December 31, 2023.

View on SEC.gov

268 earnings releases filed in the last 30 days. Browse all earnings releases →

Zymeworks Inc. filing history →

Source: SEC EDGAR

accession 0001937653-24-000017

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.